국가: 미국
언어: 영어
출처: NLM (National Library of Medicine)
Alendronate Sodium (UNII: 2UY4M2U3RA) (Alendronic acid - UNII:X1J18R4W8P)
TAGI Pharma, Inc.
Alendronate Sodium
Alendronic acid 70 mg in 75 mL
ORAL
PRESCRIPTION DRUG
Alendronate sodium is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, alendronate increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures) [see Clinical Studies ( 14.1) ] . Alendronate sodium is indicated for treatment to increase bone mass in men with osteoporosis [see Clinical Studies ( 14.3) ] . The optimal duration of use has not been determined. The safety and effectiveness of alendronate for the treatment of osteoporosis are based on clinical data of four years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically. Alendronate sodium is contraindicated in patients with the following conditions: Risk Summary: Availabl
Alendronate Sodium Oral Solution 70 mg oral solution is supplied as a clear, colorless to pale pink solution with a raspberry flavor. NDC 51224-301-10 unit-of-use cartons of 4 single-dose bottles containing 75 mL each Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Do not freeze.
Abbreviated New Drug Application
ALENDRONATE SODIUM- ALENDRONATE SODIUM SOLUTION TAGI Pharma, Inc. ---------- MEDICATION GUIDE ONCE WEEKLY Alendronate Sodium Oral Solution (a len’ droe nate soe’ dee um) Rx only Read the Medication Guide that comes with Alendronate Sodium Oral Solution before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or treatment. Talk to your doctor if you have any questions about Alendronate Sodium Oral Solution. What is the most important information I should know about Alendronate Sodium Oral Solution? Alendronate Sodium Oral Solution can cause serious side effects including: 1. Esophagus problems 2. Low calcium levels in your blood (hypocalcemia) 3. Bone, joint, or muscle pain 4. Severe jaw bone problems (osteonecrosis) 5. Unusual thigh bone fractures 1. Esophagus problems. Some people who take Alendronate Sodium Oral Solution may develop problems in the esophagus (the tube that connects the mouth and the stomach). These problems include irritation, inflammation, or ulcers of the esophagus which may sometimes bleed. • It is important that you take Alendronate Sodium Oral Solution exactly as prescribed to help lower your chance of getting esophagus problems. (See the section "How should I take once weekly Alendronate Sodium Oral Solution sodium oral solution?") • Stop taking Alendronate Sodium Oral Solution and call your doctor right away if you get chest pain, new or worsening heartburn, or have trouble or pain when you swallow. 2. Low calcium levels in your blood (hypocalcemia). Alendronate Sodium Oral Solution may lower the calcium levels in your blood. If you have low blood calcium before you start taking Alendronate Sodium Oral Solution, it may get worse during treatment. Your low blood calcium must be treated before you take Alendronate Sodium Oral Solution. Most people with low blood calcium levels do not have symptoms, but some people may have symptoms. Call your doctor 전체 문서 읽기
ALENDRONATE SODIUM- ALENDRONATE SODIUM SOLUTION TAGI PHARMA, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ALENDRONATE SODIUM ORAL SOLUTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ALENDRONATE SODIUM ORAL SOLUTION. ALENDRONATE SODIUM ORAL SOLUTION, FOR ORAL USE INITIAL U.S. APPROVAL: 1995 INDICATIONS AND USAGE Alendronate Sodium Oral Solution is a bisphosphonate indicated for: • • Limitations of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. (1.6) DOSAGE AND ADMINISTRATION • • DOSAGE FORMS AND STRENGTHS Oral Solution: 70 mg (3) CONTRAINDICATIONS • • • • • WARNINGS AND PRECAUTIONS • • • • • ADVERSE REACTIONS Most common adverse reactions (greater than or equal to 3%) are abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, musculoskeletal pain, nausea. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-800-962-8364 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS • • USE IN SPECIFIC POPULATIONS Treatment of osteoporosis in postmenopausal women (1.1) Treatment to increase bone mass in men with osteoporosis (1.3) Treatment of osteoporosis in postmenopausal women and in men: 70 mg (oral solution) once weekly. (2.1, 2.3) Instruct patients to: (2.6) o o Swallow oral solution followed by at least 2 ounces of water. Not lie down for at least 30 minutes after taking alendronate sodium oral solution and until after food. Abnormalities of the esophagus which delay emptying such as stricture or achalasia (4, 5.1) Inability to stand/sit upright for at least 30 minutes (2.6, 4, 5.1) Do not administer Alendronate Sodium Oral Solution to patients at increased risk of aspiration (4) Hypocalcemia (4, 5.2) Hypersensitivity to any component of this product (4, 6.2) _Upper Gastrointestinal Adverse Reactions_ can occur. Instruct patien 전체 문서 읽기